Sphera Funds Management
Latest statistics and disclosures from Sphera Funds Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, TEVA, SNY, CYTK, NVMI, and represent 23.90% of Sphera Funds Management's stock portfolio.
- Added to shares of these 10 stocks: XBI (+$40M), NVMI (+$18M), GLBE (+$11M), ENPH (+$8.8M), TBLA (+$7.5M), WIX (+$7.1M), PHVS (+$6.9M), META (+$6.8M), CLDX (+$6.0M), S (+$5.9M).
- Started 24 new stock positions in TBLA, PRME, FROG, ORIC, ENLT, PHVS, ENPH, PRTA, S, FIVN. NVMI, VTYX, WIX, GLBE, AVGO, CATX, FRLN, ARWR, Cargo Therapeutics, GLUE, INCY, VIGL, ARBE, UPWK.
- Reduced shares in these 10 stocks: Praxis Precision Medicines I (-$101M), Powershares Qqq Etf Put Opt 01/19 154.0 put (-$49M), Jasper Therapeutics (-$39M), TEVA (-$19M), Enphase Energy (-$17M), NICE (-$15M), GRCL (-$10M), AZN (-$7.1M), Point Biopharma Global (-$6.4M), AMZN (-$6.0M).
- Sold out of its positions in CALT, CRWD, IRON, Enphase Energy, Powershares Qqq Etf Put Opt 01/19 154.0 put, MIRM, Point Biopharma Global, VERA, XENE, QURE.
- Sphera Funds Management was a net seller of stock by $-155M.
- Sphera Funds Management has $621M in assets under management (AUM), dropping by 13.18%.
- Central Index Key (CIK): 0001496201
Tip: Access up to 7 years of quarterly data
Positions held by Sphera Funds Management consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Sphera Funds Management
Sphera Funds Management holds 91 positions in its portfolio as reported in the December 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Spdr Ser Tr S&p Biotech Put Option (XBI) | 7.2 | $45M | +900% | 500k | 89.29 |
|
Teva Pharmaceutical Inds Sponsored Ads (TEVA) | 6.3 | $39M | -33% | 3.8M | 10.44 |
|
Sanofi Sponsored Adr (SNY) | 4.0 | $25M | 500k | 49.73 |
|
|
Cytokinetics Com New (CYTK) | 3.5 | $22M | -13% | 260k | 83.49 |
|
NOVA MEASURING Instruments L (NVMI) | 2.9 | $18M | NEW | 132k | 137.39 |
|
Celldex Therapeutics Com New (CLDX) | 2.8 | $17M | +54% | 431k | 39.66 |
|
Syndax Pharmaceuticals (SNDX) | 2.7 | $17M | 773k | 21.61 |
|
|
Tower Semiconductor Shs New (TSEM) | 2.6 | $16M | +12% | 528k | 30.52 |
|
Nice Sponsored Adr (NICE) | 2.2 | $14M | -52% | 68k | 199.51 |
|
Merck & Co (MRK) | 2.2 | $14M | 124k | 109.02 |
|
|
Johnson & Johnson (JNJ) | 2.0 | $13M | -15% | 80k | 156.74 |
|
Meta Platforms Cl A (META) | 2.0 | $12M | +125% | 34k | 353.96 |
|
Astrazeneca Sponsored Adr (AZN) | 2.0 | $12M | -36% | 180k | 67.35 |
|
Biogen Idec (BIIB) | 1.9 | $12M | +79% | 46k | 258.77 |
|
Bridgebio Pharma (BBIO) | 1.8 | $11M | -18% | 282k | 40.37 |
|
Alnylam Pharmaceuticals (ALNY) | 1.7 | $11M | +55% | 56k | 191.41 |
|
Global E Online SHS (GLBE) | 1.7 | $11M | NEW | 270k | 39.63 |
|
Fusion Pharmaceuticals (FUSN) | 1.7 | $10M | -19% | 1.1M | 9.61 |
|
Kura Oncology (KURA) | 1.6 | $10M | 703k | 14.38 |
|
|
Novo-nordisk A S Adr (NVO) | 1.5 | $9.6M | 93k | 103.45 |
|
|
Ultragenyx Pharmaceutical (RARE) | 1.5 | $9.6M | -22% | 201k | 47.82 |
|
Microsoft Corporation (MSFT) | 1.4 | $9.0M | -30% | 24k | 376.04 |
|
Astria Therapeutics (ATXS) | 1.4 | $8.8M | +98% | 1.2M | 7.68 |
|
4068594 Enphase Energy (ENPH) | 1.4 | $8.8M | NEW | 67k | 132.14 |
|
Inhibrx (INBX) | 1.4 | $8.6M | -11% | 227k | 38.00 |
|
Amazon (AMZN) | 1.4 | $8.5M | -41% | 56k | 151.94 |
|
Eli Lilly & Co. (LLY) | 1.3 | $8.3M | 14k | 582.92 |
|
|
Day One Biopharmaceuticals I (DAWN) | 1.2 | $7.5M | -3% | 513k | 14.60 |
|
Taboola.com Ord Shs (TBLA) | 1.2 | $7.5M | NEW | 1.7M | 4.33 |
|
Advanced Micro Devices (AMD) | 1.2 | $7.4M | +4% | 50k | 147.41 |
|
Praxis Precision Medicines I Com New | 1.2 | $7.3M | -93% | 329k | 22.28 |
|
Abbvie (ABBV) | 1.1 | $7.1M | 46k | 154.97 |
|
|
Wix SHS (WIX) | 1.1 | $7.1M | NEW | 58k | 123.02 |
|
Solaredge Technologies (SEDG) | 1.1 | $7.0M | +39% | 75k | 93.60 |
|
Pharvaris N V (PHVS) | 1.1 | $6.9M | NEW | 245k | 28.05 |
|
Inozyme Pharma (INZY) | 1.1 | $6.7M | +26% | 1.6M | 4.26 |
|
Immatics SHS (IMTX) | 1.1 | $6.5M | 621k | 10.53 |
|
|
Madrigal Pharmaceuticals (MDGL) | 1.0 | $6.4M | -45% | 28k | 231.38 |
|
Mineralys Therapeutics (MLYS) | 1.0 | $6.4M | +63% | 744k | 8.60 |
|
Merus N V (MRUS) | 1.0 | $6.3M | -9% | 230k | 27.50 |
|
Springworks Therapeutics (SWTX) | 1.0 | $6.2M | -46% | 170k | 36.50 |
|
Novartis Sponsored Adr (NVS) | 1.0 | $6.1M | 60k | 100.97 |
|
|
Sentinelone Cl A (S) | 0.9 | $5.9M | NEW | 213k | 27.44 |
|
Rocket Pharmaceuticals (RCKT) | 0.9 | $5.7M | -8% | 191k | 29.97 |
|
Jasper Therapeutics | 0.9 | $5.6M | -87% | 713k | 7.89 |
|
Incyte Corporation (INCY) | 0.9 | $5.6M | NEW | 90k | 62.79 |
|
Gracell Biotechnologies Sponsored Ads (GRCL) | 0.8 | $5.0M | -67% | 503k | 10.04 |
|
Shl Telemedicine Sponsored Ads (SHLT) | 0.8 | $5.0M | 633k | 7.97 |
|
|
Palo Alto Networks (PANW) | 0.8 | $4.9M | -42% | 17k | 294.88 |
|
89bio (ETNB) | 0.7 | $4.6M | +27% | 409k | 11.17 |
|
Alpine Immune Sciences (ALPN) | 0.7 | $4.5M | +30% | 235k | 19.06 |
|
Arrowhead Pharmaceuticals (ARWR) | 0.7 | $4.4M | NEW | 145k | 30.60 |
|
Amylyx Pharmaceuticals (AMLX) | 0.7 | $4.2M | +46% | 284k | 14.72 |
|
Vistagen Therapeutics Ord (VTGN) | 0.7 | $4.2M | +708% | 809k | 5.14 |
|
Jfrog Ord Shs (FROG) | 0.6 | $3.8M | NEW | 110k | 34.61 |
|
Ptc Therapeutics I (PTCT) | 0.6 | $3.8M | -37% | 137k | 27.56 |
|
Upwork (UPWK) | 0.6 | $3.8M | NEW | 253k | 14.87 |
|
Sarepta Therapeutics (SRPT) | 0.6 | $3.8M | -22% | 39k | 96.43 |
|
GSK Sponsored Adr (GSK) | 0.6 | $3.7M | 100k | 37.06 |
|
|
Pliant Therapeutics (PLRX) | 0.6 | $3.5M | +23% | 194k | 18.11 |
|
Enlight Renewable Energy SHS (ENLT) | 0.5 | $3.2M | NEW | 169k | 19.14 |
|
Pfizer (PFE) | 0.4 | $2.6M | 90k | 28.79 |
|
|
Prothena Corp SHS Call Option (PRTA) | 0.4 | $2.5M | NEW | 68k | 36.34 |
|
Werewolf Therapeutics (HOWL) | 0.4 | $2.4M | 627k | 3.86 |
|
|
Promis Neurosciences Com New (PMN) | 0.3 | $2.1M | 1.8M | 1.15 |
|
|
Icl Group SHS (ICL) | 0.3 | $2.1M | -10% | 420k | 5.01 |
|
Broadcom (AVGO) | 0.3 | $2.0M | NEW | 1.8k | 1116.25 |
|
Kezar Life Sciences (KZR) | 0.3 | $1.9M | 2.1M | 0.95 |
|
|
Vigil Neuroscience (VIGL) | 0.3 | $1.8M | NEW | 535k | 3.38 |
|
Rigel Pharmaceuticals Com New (RIGL) | 0.3 | $1.8M | 1.2M | 1.45 |
|
|
Cargo Therapeutics | 0.3 | $1.7M | NEW | 75k | 23.15 |
|
Gilead Sciences (GILD) | 0.3 | $1.6M | -50% | 20k | 81.01 |
|
Cogent Biosciences (COGT) | 0.2 | $1.5M | -38% | 259k | 5.88 |
|
Compugen Ord (CGEN) | 0.2 | $1.5M | -41% | 769k | 1.98 |
|
Gossamer Bio (GOSS) | 0.2 | $1.2M | -30% | 1.3M | 0.91 |
|
Five9 (FIVN) | 0.2 | $1.2M | NEW | 15k | 78.69 |
|
Oric Pharmaceuticals (ORIC) | 0.2 | $1.2M | NEW | 127k | 9.20 |
|
Rezolute Com New (RZLT) | 0.2 | $989k | 997k | 0.99 |
|
|
Apogee Therapeutics (APGE) | 0.1 | $838k | 30k | 27.94 |
|
|
Prime Medicine (PRME) | 0.1 | $656k | NEW | 74k | 8.86 |
|
Selecta Biosciences (RNAC) | 0.1 | $519k | 752k | 0.69 |
|
|
Mediwound Shs New (MDWD) | 0.1 | $498k | -54% | 49k | 10.17 |
|
Elevation Oncology (ELEV) | 0.1 | $483k | 900k | 0.54 |
|
|
Ventyx Biosciences (VTYX) | 0.1 | $445k | NEW | 180k | 2.47 |
|
Morphic Hldg (MORF) | 0.1 | $432k | -83% | 15k | 28.88 |
|
Immatics *w Exp 07/01/202 (IMTXW) | 0.0 | $292k | 100k | 2.92 |
|
|
Monte Rosa Therapeutics (GLUE) | 0.0 | $274k | NEW | 49k | 5.65 |
|
Replimune Group (REPL) | 0.0 | $136k | -91% | 16k | 8.43 |
|
Freeline Therapeutics Hldgs Sponsored Ads (FRLN) | 0.0 | $105k | NEW | 16k | 6.37 |
|
Arbe Robotics Ordinary Shares (ARBE) | 0.0 | $94k | NEW | 43k | 2.18 |
|
IsoRay (CATX) | 0.0 | $10k | NEW | 26k | 0.40 |
|
Past Filings by Sphera Funds Management
SEC 13F filings are viewable for Sphera Funds Management going back to 2013
- Sphera Funds Management 2023 Q4 restated filed Feb. 15, 2024
- Sphera Funds Management 2023 Q4 filed Feb. 14, 2024
- Sphera Funds Management 2023 Q3 filed Nov. 14, 2023
- Sphera Funds Management 2023 Q2 filed Aug. 14, 2023
- Sphera Funds Management 2023 Q1 filed May 15, 2023
- Sphera Funds Management 2022 Q4 filed Feb. 14, 2023
- Sphera Funds Management 2022 Q3 filed Nov. 14, 2022
- Sphera Funds Management 2022 Q2 filed Aug. 15, 2022
- Sphera Funds Management 2022 Q1 filed May 16, 2022
- Sphera Funds Management 2021 Q4 filed Feb. 14, 2022
- Sphera Funds Management 2021 Q3 filed Nov. 15, 2021
- Sphera Funds Management 2021 Q2 filed Aug. 17, 2021
- Sphera Funds Management 2021 Q1 filed May 17, 2021
- Sphera Funds Management 2020 Q4 filed Feb. 16, 2021
- Sphera Funds Management 2020 Q3 filed Nov. 12, 2020
- Sphera Funds Management 2020 Q2 filed Aug. 13, 2020